Dr. Postow Discusses Side Effects with Combinations in Melanoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine